DK1240186T3 - Forbedringer i eller relateret til immunrespons mod HIV - Google Patents

Forbedringer i eller relateret til immunrespons mod HIV

Info

Publication number
DK1240186T3
DK1240186T3 DK00985690.7T DK00985690T DK1240186T3 DK 1240186 T3 DK1240186 T3 DK 1240186T3 DK 00985690 T DK00985690 T DK 00985690T DK 1240186 T3 DK1240186 T3 DK 1240186T3
Authority
DK
Denmark
Prior art keywords
hiv
immune response
immunogen
synthetic polypeptide
protein
Prior art date
Application number
DK00985690.7T
Other languages
English (en)
Inventor
Tomas Hanke
Andrew James Mcmichael
Original Assignee
Medical Res Council
Int Aids Vaccine Initiative
Univ Nairobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930294.5A external-priority patent/GB9930294D0/en
Priority claimed from GB0025234A external-priority patent/GB0025234D0/en
Application filed by Medical Res Council, Int Aids Vaccine Initiative, Univ Nairobi filed Critical Medical Res Council
Application granted granted Critical
Publication of DK1240186T3 publication Critical patent/DK1240186T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00985690.7T 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV DK1240186T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930294.5A GB9930294D0 (en) 1999-12-23 1999-12-23 Improvements in or relating to immune responses to HIV
GB0025234A GB0025234D0 (en) 2000-10-14 2000-10-14 Improvements in or relating to immune responses to HIV
PCT/GB2000/004984 WO2001047955A2 (en) 1999-12-23 2000-12-22 Improvements in or relating to immune responses to hiv

Publications (1)

Publication Number Publication Date
DK1240186T3 true DK1240186T3 (da) 2010-05-31

Family

ID=26245157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00985690.7T DK1240186T3 (da) 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV

Country Status (15)

Country Link
US (1) US7993651B2 (da)
EP (1) EP1240186B1 (da)
JP (1) JP4805511B2 (da)
CN (1) CN1213068C (da)
AT (1) ATE457996T1 (da)
AU (1) AU784679B2 (da)
BR (1) BR0016510A (da)
CA (1) CA2392877C (da)
CY (1) CY1110917T1 (da)
DE (1) DE60043856D1 (da)
DK (1) DK1240186T3 (da)
ES (1) ES2341429T3 (da)
MX (1) MXPA02006379A (da)
PT (1) PT1240186E (da)
WO (1) WO2001047955A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CN1311871C (zh) 2000-03-02 2007-04-25 爱莫里大学 Dna表达载体及其应用方法
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
JP4554887B2 (ja) 2001-03-08 2010-09-29 アメリカ合衆国 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
IL160809A0 (en) * 2001-09-20 2004-08-31 Glaxo Group Ltd HIV-gag CODON-OPTIMISED DNA VACCINES
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
CA2519025A1 (en) * 2003-03-28 2004-10-07 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
ES2388527T3 (es) 2003-09-15 2012-10-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vacunas de VIH basadas en Env de múltiples clados de VIH
WO2005030964A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
JP4772045B2 (ja) * 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006123256A2 (en) * 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
CA2654324A1 (en) 2006-06-02 2007-12-13 International Aids Vaccine Initiative Hiv-1 clade a consensus sequences, antigens, and transgenes
WO2010096561A1 (en) * 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
CA2767924A1 (en) * 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2012062873A2 (en) * 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014040025A2 (en) 2012-09-10 2014-03-13 International Aids Vaccine Initiative Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3116895A4 (en) * 2014-03-12 2017-08-16 Temple University Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
WO2017156170A1 (en) 2016-03-09 2017-09-14 University Of Massachusetts Use of modified hiv-1 for generating fully human antibodies
CA3145833A1 (en) * 2019-07-02 2021-01-07 Roman YELENSKY Hiv antigens and mhc complexes
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2869063B2 (ja) 1985-04-08 1999-03-10 ジエネテイツク システムズ コ−ポレイシヨン ＬＡＶに対する抗体と免疫的に反応性であるｇａｇによりコードされたペプチドの発現及び使用
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5175098A (en) 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV
US5175097A (en) 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with antibodies to HIV
US4808536A (en) 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US5134227A (en) 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
DE346022T1 (de) 1988-06-10 1990-05-23 Medical Research Council, London Peptidfragmente von hiv.
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
US5210181A (en) 1989-05-15 1993-05-11 Akzo N.V. T-lymphotropic retrovirus peptide
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
EP0510054A1 (en) 1990-01-05 1992-10-28 United Biomedical, Inc. Hiv-1 core protein fragments
CA2084386C (en) * 1992-06-04 2001-02-20 Atsushi Saito Hiv antigen
DK0591914T4 (da) 1992-10-06 2010-05-25 Siemens Healthcare Diagnostics Retrovirus fra HIV-gruppen og dets anvendelse
CA2164818C (en) 1993-06-09 2003-09-23 Charles D.Y. Sia Tandem synthetic hiv-1 peptides
US6225045B1 (en) 1996-05-13 2001-05-01 Ribotargets, Ltd. Assays for screening for inhibitors of HIV
JP2001505763A (ja) 1996-08-09 2001-05-08 バイラル・テクノロジーズ・インコーポレーテツド Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
WO1998043669A1 (en) 1997-04-03 1998-10-08 Thomas Jefferson University Chimeric viral proteins
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
CA2350911A1 (en) * 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1088889A1 (en) 1999-10-01 2001-04-04 University Of Cambridge Recombinant double hybrid filamentous bacteriophage

Also Published As

Publication number Publication date
CN1213068C (zh) 2005-08-03
EP1240186B1 (en) 2010-02-17
WO2001047955A3 (en) 2002-05-10
CY1110917T1 (el) 2015-06-10
PT1240186E (pt) 2010-03-25
CA2392877C (en) 2011-11-15
EP1240186A2 (en) 2002-09-18
CN1434831A (zh) 2003-08-06
JP4805511B2 (ja) 2011-11-02
ES2341429T3 (es) 2010-06-21
WO2001047955A2 (en) 2001-07-05
BR0016510A (pt) 2002-08-27
AU2208901A (en) 2001-07-09
DE60043856D1 (de) 2010-04-01
HK1058048A1 (en) 2004-04-30
MXPA02006379A (es) 2004-06-21
CA2392877A1 (en) 2001-07-05
US20030108562A1 (en) 2003-06-12
US7993651B2 (en) 2011-08-09
AU784679B2 (en) 2006-05-25
ATE457996T1 (de) 2010-03-15
JP2003518931A (ja) 2003-06-17

Similar Documents

Publication Publication Date Title
DK1240186T3 (da) Forbedringer i eller relateret til immunrespons mod HIV
Rusche et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
Haigwood et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies
Albert et al. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
Fast et al. Human trials of experimental AIDS vaccines
EP1601328A2 (en) Polyvalent immunogen
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Clerici et al. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
HK141594A (en) Peptide fragments of HIV and their use in vaccines and diagnosis
RU2002126396A (ru) Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
Earl et al. Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques
WO1998041536A9 (en) Glycosylation deficient siv and hiv envelope glycoproteins
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
Böttiger et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
OA10271A (en) Multiple branch peptide constructions for use against hiv
DE69217614D1 (de) Hybride, lösliche und nicht gespaltene gp160-variante
WO2005016952A2 (en) Polyvalent immunogen
Clutton et al. Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines
Nardelli et al. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant
Okuda et al. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection
Benjouad et al. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type‐1 envelope glycoprotein